text_1: Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.
text_2: Finally, a triple combination of DNMTi/HDACi plus the immune checkpoint inhibitor α-PD-1 provides the best antitumor effect and longest overall survival, and may be an attractive candidate for future clinical trials in ovarian cancer.